IFF Beats Q3, Lifts 2026 Outlook, Wraps $500M Buyback — But Warns on Q4
IFF sits 45% above its 52-week low of $61.295.
Summary
IFF beat on the top line with Q3 sales of $1.942 billion, up 4%, and adjusted EBITDA of $403 million, up 5%, with Scent up 10% and Taste up 7% on segment EBITDA. Management raised its 2026 sales and EBITDA outlooks and finished the $500 million accelerated share repurchase. The catch: higher costs and reinvestment in Health & Biosciences are expected to pressure Q4 profits, so the raise comes with a softer near-term margin setup. The GAAP loss of $55 million traces to a $236 million charge on the Botanicals & Food Enhancements business being sold, not operations. The Food Ingredients sale is still expected to close in Q2 2027, with SCL now in discontinued operations.
At the time of this announcement, IFF was trading at $89.00 on NYSE in the Manufacturing sector, with a market capitalization of approximately $23.5B. The 52-week trading range was $61.30 to $95.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.